Mitigation of Stenosis with Electrical Fields in Vascular Access Applications

Information

  • Research Project
  • 7671638
  • ApplicationId
    7671638
  • Core Project Number
    R43DK081253
  • Full Project Number
    1R43DK081253-01A1
  • Serial Number
    81253
  • FOA Number
    PA-08-050
  • Sub Project Id
  • Project Start Date
    5/1/2009 - 15 years ago
  • Project End Date
    4/30/2012 - 12 years ago
  • Program Officer Name
    MOXEY-MIMS, MARVA M.
  • Budget Start Date
    5/1/2009 - 15 years ago
  • Budget End Date
    4/30/2012 - 12 years ago
  • Fiscal Year
    2009
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    5/1/2009 - 15 years ago
Organizations

Mitigation of Stenosis with Electrical Fields in Vascular Access Applications

DESCRIPTION (provided by applicant): Management of cellular motility and subsequent hyperplasia with Electric Fields (EF) offers the potential to have a significant impact in managing stenosis in a variety of clinical applications including coronary and peripheral arterial stenting, and arteriovenous access in hemodialysis. As a first step towards this goal of active management of stenosis utilizing EF, this proof of concept SBIR Phase I proposal will demonstrate the ability of applied electric fields to mitigate stenosis in an angioplasty injury model. This model creates long-term vascular remodeling associated with neointimal formation in vivo. The proposed preclinical studies will assess the impact of various applied electric fields on neointimal growth following vascular injury in this model system. Effectiveness of the technology will be made by comparing intimal and medial areas of transverse sections of injured arteries in the presence of the electric fields as compared to control /inactive EF electrodes in the same vessel. This initial proof of concept work will provide the basis for future planned studies in more complex model systems, e.g. AV graft models, designed to optimize efficacy. PUBLIC HEALTH RELEVANCE: The results of this Phase-1 SBIR proposal offers the foundation of a disruptive advance in mitigating stenosis in several clinical applications including coronary and peripheral arterial stenting, and arteriovenous access in hemodialysis. In particular, the long term focus of this first application of the EF technology is the huge unmet clinical need associated with hemodialysis vascular access dysfunction (arteriovenous dialysis grafts or fistulae). This unmet clinical need represents the second largest expenditure by Medicare for these hemodialysis patients, next to the hemodialysis treatment itself. The failure rates for graft dysfunction are a direct consequence of stenosis due to intimal hyperplasia at the graft-vein anastomosis, and the current therapeutic interventions have very poor efficacy, are complex and costly.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R43
  • Administering IC
    DK
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    266531
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:266531\
  • Funding Mechanism
    SBIR-STTR
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    PHILOMETRON, INC.
  • Organization Department
  • Organization DUNS
    101667405
  • Organization City
    SAN DIEGO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    921211053
  • Organization District
    UNITED STATES